---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-130854"
form_type: "8-K"
ticker: "FENC"
cik: "0001211583"
company_name: "FENNEC PHARMACEUTICALS INC."
filed_at: "2024-12-20T23:59:59+00:00"
generated_at: "2026-05-29T00:05:06.892315+00:00"
event_type: "debt"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Fennec repays $13M convertible debt; eliminates $1.5M annual interest

## Summary
- Repurchased and redeemed $13M of convertible notes on Dec 18, 2024; fully retires First and Third Closing Notes.
- Financed entirely from available cash; eliminates ~$1.5M in annual interest expense.
- Pro forma debt facility with Petrichor is ~$19.2M, maturity Sept 2027.
- Eliminates potential dilution of ~1.6 million shares from repaid notes.
- CEO confirms cash sufficient to fund operations into 2026.

## SEC filing metadata
- accession: 0001104659-24-130854
- form_type: 8-K
- ticker: FENC
- cik: 0001211583
- company_name: FENNEC PHARMACEUTICALS INC.
- filed_at: 2024-12-20T23:59:59+00:00
- event_type: debt
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1211583/000110465924130854/0001104659-24-130854-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1211583/000110465924130854/tm2431725d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-130854
- JSON: https://secwatch.observer/filing/0001104659-24-130854.json
- Plain text: https://secwatch.observer/filing/0001104659-24-130854.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.